Moderna (MRNA) Rockets 17% on Strong Preliminary FY25 Results

Group 1 - Moderna Inc. reported a strong performance with a 17.02% increase in stock price, closing at $39.60, driven by positive preliminary earnings results for full-year 2025 [1][3] - The company expects revenues of $1.9 billion for full-year 2025, exceeding its previous guidance range of $1.6 billion to $2 billion [2] - Moderna aims for up to 10% revenue growth in 2026 while reducing operating expenses to between $4.2 billion and $4.6 billion, with a goal to break even by 2028 [2][4] Group 2 - CEO Stephane Bancel highlighted the successful launch of a third product and significant cost reductions of approximately $2 billion, surpassing initial financial commitments [3] - The company is focused on building a seasonal vaccine franchise for at-risk populations, which is expected to support revenue growth and fund future innovations in oncology and rare diseases [4] - Official financial results are anticipated to be released in the second week of next month [4]